Cargando…

TIMAP Upregulation Correlates Negatively with Survival in HER2- Negative Subtypes of Breast Cancer

OBJECTIVE: TIMAP expression is regulated by transforming growth factor beta 1 (TGFβ1); known for its role in breast cancer development and metastasis. Nevertheless, data on TIMAP protein expression and its association with breast cancer development are lacking. In this study, we aimed to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Obeidat, Marya, Bodoor, Khaldon, Alqudah, Mohammad, Masaadeh, Amr, Barukba, Marwa, Almomani, Rowida
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418848/ https://www.ncbi.nlm.nih.gov/pubmed/34181349 http://dx.doi.org/10.31557/APJCP.2021.22.6.1899

Ejemplares similares

LAT1 (SLC7A5) Overexpression in Negative Her2 Group of Breast Cancer: A Potential Therapy Target
por: Bodoor, Khaldon, et al.
Publicado: (2020)

Evaluation of Patched-1 Protein Expression Level in Low Risk and High Risk Basal Cell Carcinoma Subtypes
por: Almomani, Rowida, et al.
Publicado: (2019)

Clinical and Demographic Features of Basal Cell Carcinoma in North Jordan
por: Al-Qarqaz, Firas, et al.
Publicado: (2018)

IL-33/13 Axis and IL-4/31 Axis Play Distinct Roles in Inflammatory Process and Itch in Psoriasis and Atopic Dermatitis
por: Bodoor, Khaldon, et al.
Publicado: (2020)

Basal Cell Carcinoma Pathology Requests and Reports Are Lacking Important Information
por: Al-Qarqaz, Firas, et al.
Publicado: (2019)

Erratum to “Basal Cell Carcinoma Pathology Requests and Reports Are Lacking Important Information”
por: Al-Qarqaz, Firas, et al.
Publicado: (2019)

TIMAP inhibits endothelial myosin light chain phosphatase by competing with MYPT1 for the catalytic protein phosphatase 1 subunit PP1cβ
por: Wang, Xin, et al.
Publicado: (2019)

Hereditary multiple osteochondromas in Jordanian patients: Mutational and immunohistochemical analysis of EXT1 and EXT2 genes
por: Mohaidat, Ziyad, et al.
Publicado: (2021)

The role of LR-TIMAP/PP1c complex in the occurrence and development of no-reflow
por: Quan, Xiaoyu, et al.
Publicado: (2021)

Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes
por: Utsumi, Toshiaki, et al.
Publicado: (2021)

Frequency of the Hemochromatosis Gene (HFE) Variants in a Jordanian Arab Population and in Diabetics from the Same Region
por: Alkhateeb, Asem, et al.
Publicado: (2009)

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
por: MacNeil, Ian A., et al.
Publicado: (2020)

Pharmacogenetic Study of the Dihydropyridine Dehydrogenase Gene in Jordanian Patients with Colorectal Cancer
por: Almashagbah, Nusaiba A., et al.
Publicado: (2022)

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021)

HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers
por: Wang, Tonghui, et al.
Publicado: (2017)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

Hyperbaric oxygen exposure alleviate metabolic side-effects of olanzapine treatment and is associated with Langerhans islet proliferation in rats
por: AlQudah, Mohammad, et al.
Publicado: (2022)

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
por: Xie, Peiling, et al.
Publicado: (2021)

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
por: Ascione, Liliana, et al.
Publicado: (2022)

Nup84, A Novel Nucleoporin That Is Associated With CAN/Nup214 on the Cytoplasmic Face of the Nuclear Pore Complex
por: Bastos, Ricardo, et al.
Publicado: (1997)

Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy
por: Chaudhary, Lubna Naaz, et al.
Publicado: (2023)

Identification of a novel WFS1 homozygous nonsense mutation in Jordanian children with Wolfram syndrome
por: Bodoor, Khaldon, et al.
Publicado: (2016)

HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2‐negative patients
por: Si, Pilei, et al.
Publicado: (2017)

A nomogram for predicting the HER2 status of circulating tumor cells and survival analysis in HER2-negative breast cancer
por: Yang, Yuqin, et al.
Publicado: (2022)

Genetics of Female Infertility: Molecular Study of Newborn Ovary Homeobox Gene in Poor Ovarian Responders
por: Batiha, Osamah, et al.
Publicado: (2019)

Post-acne hyperpigmentation: Evaluation of risk factors and the use of artificial neural network as a predictive classifier
por: Al-Qarqaz, Firas, et al.
Publicado: (2021)

Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer
por: Yoder, Rachel, et al.
Publicado: (2022)

The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer
por: Liao, Hong-Ye, et al.
Publicado: (2018)

Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer
por: Lundgren, Christine, et al.
Publicado: (2019)

Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype
por: Yanagawa, Masumi, et al.
Publicado: (2012)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

Bevacizumab in the treatment of HER2-negative breast cancer
por: Lorusso, Vito
Publicado: (2008)

Bevacizumab in HER2-negative inflammatory breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

LINGUISTIC COMPENTENCE IN POSITIVE AND NEGATIVE SUBTYPES OF SCHIZOPHRENIA
por: Giridhar, C., et al.
Publicado: (1992)

p-STAT3 expression in breast cancer correlates negatively with tumor size and HER2 status
por: Wang, Yan, et al.
Publicado: (2021)

Lumpectomy followed by radiation improves survival in HER2 positive and triple‐negative breast cancer with high tumor‐infiltrating lymphocytes compared to mastectomy alone
por: Mouabbi, Jason A., et al.
Publicado: (2021)

Reversal of HER2 Negativity: An Unexpected Role for Lovastatin in Triple-Negative Breast Cancer Stem Cells
por: Yi, Huimei, et al.
Publicado: (2020)

Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
por: Diana, Anna, et al.
Publicado: (2022)

Recurrent Metaplastic Breast Cancer with Subtype Converted from Triple-Negative to HER2-Positive: A Case Report and Literature Review
por: Wu, Jing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pc3n14ng6la33gh8horlv78vct